Literature DB >> 2843005

Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin).

E Persson1.   

Abstract

Heparin activates lipoprotein lipase (LPL) and hepatic lipase (HL), enhances plasma lipolytic activity and elevates plasma levels of free fatty acids (FFA). The metabolic consequences of this effect are controversial. In this study the plasma lipolytic effect of unfractionated heparin (mean molecular weight, MW, 12,000-15,000) was compared with that of a low molecular weight heparin (LMWH) fragment (Kabi 2165, Fragmin, mean MW 4000-6000). The comparisons which were carried out in vivo and in vitro in both man and rat were based on the antifactor Xa activity of the two heparins. After i.v. injection of LMWH the release of LPL activity was only half as great as with heparin and the increase in plasma FFA was significantly lower. The immediate release of HL activity was the same for both heparins, the release of LPL activity was dose-dependent and the elimination followed first-order kinetics. After subcutaneous administration, LMWH was absorbed faster than heparin but still had a negligible effect on plasma lipolysis. With simultaneous i.v. infusions of fat emulsion, glucose and heparin or LMWH to healthy subjects no different effects on fat oxidation were seen in spite of pathological increases in plasma FFA with heparin. Also, heat production from isolated adipocytes was not affected by heparin or LMWH. Enzyme release was greater with LMWH in tissue preparations of fat, skeletal muscle and heart muscle in vitro, however. In isolated fat cells no difference in the release of LPL was seen between the two heparins. In conclusion, the plasma lipolytic effect of LMWH is significantly weaker than that of heparin. The complex-binding between heparin and LPL is dependent on the degree of sulphation or ionic strength of the heparin. In the LPL-release from tissue preparations, the molecular size of the heparin is of greater significance, however. Regardless of the degree of plasma lipolytic activity of the two heparin preparations, the fat oxidation rate is not affected. Considering the toxic effects of high levels of plasma FFA, LMWH, with its weak lipolytic potential would appear to be preferable to heparin as an anticoagulant agent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843005

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  17 in total

1.  Volume-selective 1H MR spectroscopy for in vivo detection of valproate in patients with epilepsy.

Authors:  S Seyfert; J Bernarding; J Braun
Journal:  Neuroradiology       Date:  2003-03-27       Impact factor: 2.804

Review 2.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

3.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.

Authors:  Vasken Dilsizian; Stephen L Bacharach; Rob S Beanlands; Steven R Bergmann; Dominique Delbeke; Sharmila Dorbala; Robert J Gropler; Juhani Knuuti; Heinrich R Schelbert; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2016-07-08       Impact factor: 5.952

Review 4.  ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Keiichiro Yoshinaga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

Review 5.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 6.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

7.  In vivo 1H magnetic resonance spectroscopy of rat brain after valproate administration.

Authors:  J Leib; J Braun; A Schilling; C Klingner; S Seyfert; W Vollmann; E Gedat; J Bernarding
Journal:  Neuroradiology       Date:  2004-03-25       Impact factor: 2.804

8.  Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Shinji Ishimaru; Noriko Oyama; Toshiki Takei; Eriko Tsukamoto; Masatake Miura; Shinji Sakaue; Nagara Tamaki; Masaharu Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-15       Impact factor: 9.236

9.  Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme.

Authors:  Birgit Näsström; Bernd Stegmayr; Gunilla Olivecrona; Thomas Olivecrona
Journal:  BMC Nephrol       Date:  2004-11-03       Impact factor: 2.388

10.  Diabeto-anaesthesia: A subspecialty needing endocrine introspection.

Authors:  Sukhminder Jit Singh Bajwa; Sanjay Kalra
Journal:  Indian J Anaesth       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.